Patents
Literature
346 results about "Transferrin receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Transferrin receptor (TfR) is a carrier protein for transferrin. It is needed for the import of iron into the cell and is regulated in response to intracellular iron concentration. It imports iron by internalizing the transferrin-iron complex through receptor-mediated endocytosis. The existence of a receptor for transferrin iron uptake had been recognized over half a century back. Earlier two transferrin receptors in humans, transferrin receptor 1 and transferrin receptor 2 had been characterized and until recently cellular iron uptake was believed to occur chiefly via these two well documented transferrin receptors. Both these receptors are transmembrane glycoproteins. TfR1 is a high affinity ubiquitously expressed receptor while expression of TfR2 is restricted to certain cell types and is unaffected by intracellular iron concentrations. TfR2 binds to transferrin with a 25-30 fold lower affinity than TfR1. Although TfR1 mediated iron uptake is the major pathway for iron acquisition by most cells and especially developing erythrocytes, several studies have indicated that the uptake mechanism varies depending upon the cell type. It is also reported that Tf uptake exists independent of these TfRs although the mechanisms are not well characterized. The multifunctional glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH,EC 1.2.1.12) has been shown to utilize post translational modifications to exhibit higher order moonlighting behavior wherein it switches its function as a holo or apo transferrin receptor leading to either iron delivery or iron export respectively.
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
ActiveUS12173079B2Organic active ingredientsSpecial deliveryAntiendomysial antibodiesInternalization
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC
Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
Aspects of the disclosure relate to oligonucleotides designed to target DUX4 RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease (e.g., FSHD). Wherein a complex comprises an anti-transferrin receptor 1 (TfR1) antibody covalently linked to an oligonucleotide configured for reducing expression or activity of DUX4.
Owner:DYNE THERAPEUTICS INC
Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject
ActiveUS12329825B1Organic active ingredientsSplicing alterationAntiendomysial antibodiesMutant allele
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Owner:DYNE THERAPEUTICS INC
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC
Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
ActiveUS12370264B1Cell receptors/surface-antigens/surface-determinantsSpecial deliveryDiseaseAntiendomysial antibodies
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC
Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Owner:DYNE THERAPEUTICS INC
Therapeutic use of bispecific Anti-abeta / TFR antibodies
PCT designated stage expiredWO2024246085A1Nervous disorderAntibody ingredientsDiseaseAntiendomysial antibodies
Herein is reported a bispecific antibody specifically binding to human Abeta protein and human transferrin receptor (bispecific anti-Abeta / TfR antibody) as well as the use of such bispecific antibodies as a medicament in the treatment of Alzheimer's Disease, including where the bispecific antibody is administered intravenously at a dose of 0.2 mg / kg to 7.2 mg / kg once every four weeks.
Owner:F HOFFMANN LA ROCHE & CO AG +1
Ferritin-gold nanoparticle conjugates for photodynamic cancer therapy
PCT designated stage expiredWO2025006911A1Material nanotechnologyPowder deliveryCancer therapyCancer research
The present invention provides a composition comprising a Ferritin-metal nanoparticle bioconjugate, wherein the Ferritin-metal nanoparticle bioconjugate comprises at least one metal nanoparticle and at least one Ferritin or a variant or a fragment thereof conjugated to the at least one metal nanoparticle; and wherein the Ferritin-metal nanoparticle bioconjugate specifically targets at least one cell expressing a transferrin receptor 1 (TfR1), and methods of making and use thereof.
Owner:TEMPLE UNIV
Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC
Anti-transferrin receptor antibodies and uses thereof cross reference to related applications
PCT designated stage expiredWO2025090898A1Nervous disorderMuscular disorderAntiendomysial antibodiesPolynucleotide
The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of use for delivery of cargo to brain tissue. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.
Owner:BIOGEN MA INC
Anti-transferrin receptor antibody with customized affinity
Disclosed herein is an anti-transferrin receptor antibody that specifically binds to the human transferrin receptor and the rhesus monkey transferrin receptor, comprising i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO:01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO:26, wherein the dissociation rate of the antibody for the human transferrin receptor is equal to or less than (i.e., at most) the dissociation rate of anti-transferrin receptor antibody 128.1 for the rhesus monkey transferrin receptor, wherein the dissociation rate is determined by surface plasmon resonance, and anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO:64 and a light chain variable domain of SEQ ID NO:65.
Owner:F HOFFMANN LA ROCHE & CO AG
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
Disclosed herein are antibody oligonucleotide conjugates and pharmaceutical compositions that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping. Also described herein include methods for treating muscle dystrophy including Duchenne muscular dystrophy that comprises administering antibody oligonucleotide conjugates or a pharmaceutical composition that induces alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping.
Owner:AVIDITY BIOSCI INC
Bispecific anti-human A-beta / anti-human transferrin receptor antibodies
Herein are provided bispecific anti-human A-beta / human transferrin receptor antibodies and methods of using the same.
Owner:F HOFFMANN LA ROCHE INC
AAV capsid for CNS-range gene delivery by interaction with transferrin receptors
The present letter invention provides an engineered AAV capsid in which at least one protein on the capsid is modified to include an n-mer motif that promotes transduction of the capsid into the central nervous system (CNS) by interaction with a transferrin receptor. Further embodiments provide a carrier system comprising one or more carriers encoding an AAV capsid and a method of delivering a cargo to a CNS. The methods comprise administering an AAV capsid according to embodiments described herein in vivo or in vitro, and the AVV capsid comprises one or more carrier molecules.
Owner:THE BROAD INST INC
Drug delivery compound, oligonucleotide conjugate and application thereof
The invention relates to a transferrin receptor-targeting drug delivery compound as shown in a formula I, an oligonucleotide conjugate and application of the transferrin receptor-targeting drug delivery compound and the oligonucleotide conjugate. The compounds of the present invention are capable of efficiently delivering oligonucleotides to target organs or target tissues. # imgabs0 #
Owner:SUZHOU XIANXING EXCELLENT BIOTECHNOLOGY CO LTD
Therapeutic Use of Bispecific Anti-Abeta / TfR Antibodies
Herein is reported a bispecific antibody specifically binding to human Abeta protein and human transferrin receptor (bispecific anti-Abeta / TfR antibody) as well as the use of such bispecific antibodies as a medicament in the treatment of Alzheimer's Disease, including where the bispecific antibody is administered intravenously at a dose of 0.2 mg / kg to 7.2 mg / kg once every four weeks.
Owner:F HOFFMANN LA ROCHE INC
PH-sensitive humanized anti-transferrin receptor 1 antibody
The invention relates to the technical field of antibodies, in particular to a pH-sensitive humanized anti-transferrin receptor 1 antibody. The invention designs a pH-sensitive human anti-transferrin receptor 1 antibody or an antigen binding fragment thereof, the antibody has good binding activity to TfR1 under a neutral pH condition, the binding activity is obviously reduced or lost under a low pH condition, and the antibody can more efficiently penetrate through a blood-brain barrier to be delivered into the brain through a TfR1-mediated endocytosis transport effect by utilizing the pH-sensitive characteristic, so that the human anti-transferrin receptor 1 antibody or the antigen binding fragment thereof can be applied to the brain. The drug delivery system can be used as a delivery carrier of drugs for treating central nervous system diseases, and has a wide application prospect.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES
Blood-brain barrier crossing antibodies
The present invention relates to antibodies or antibody fragments that bind to human and non-human primate transferrin receptors. The antibodies described herein can be used as agents to deliver pharmaceutical compounds into or through cells during receptor-mediated endocytosis and / or transendocytosis processes. As transferrin receptors are also present in the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase delivery of pharmaceutical compounds to the central nervous system.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +1
Preparation method of polymer vesicle capable of crossing blood brain barrier
PendingCN120694949AOrganic active ingredientsNervous disorderAntiendomysial antibodiesBiocompatibility
The invention discloses a preparation method of a polymer vesicle capable of crossing a blood brain barrier, and belongs to the field of high polymer materials and medical engineering. The preparation method of the polymer vesicle capable of crossing the blood brain barrier comprises the following steps: synthesizing an amphiphilic block copolymer by utilizing ring-opening polymerization reaction of polycaprolactone and anhydride in an amino acid ring, then assembling the polymer into the polymer vesicle, and modifying a monoclonal antibody of a transferrin receptor on a polypeptide chain. The polymer vesicle prepared by the invention is simple and convenient in preparation process, short in period, good in stability, good in biocompatibility and good in biodegradability, can be used as an excellent carrier of chemotherapeutic drugs, and can effectively realize drug delivery of targeting brain tumor cells across a blood brain barrier. Compared with a commercial drug delivery carrier, the polymer vesicle has the advantage that the permeability of the drug in a bionic blood brain barrier and the targeted uptake rate of brain tumor cells are remarkably improved.
Owner:JIANGNAN UNIV
siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2
Provided is novel siRNA having an RNA interfering action and / or a gene expression suppressing action on mRNA encoding TfR2, or the like. An oligonucleotide or a pharmaceutically acceptable salt thereof, or the like, has a knockdown action on mRNA of transferrin receptor 2, and consists of an antisense strand region containing a target-matching sequence substantially complementary to a target sequence in mRNA encoding TfR2, and a sense strand region containing a nucleotide sequence substantially complementary to the target-matching sequence of the antisense strand region.
Owner:DAIICHI SANKYO CO LTD
Improved Linkers and Methods for the Synthesis of Anti-Transferrin Receptor Antibody Conjugates
PCT designated stageWO2025160218A1Organic chemistryPharmaceutical non-active ingredientsAntiendomysial antibodiesAntibody conjugate
The present disclosure relates to improved linkers for conjugating oligonucleotidebased agents (e.g., RNAi agents) to an antibody or antibody fragment (e.g., anti-transferrin receptor (TfR1) antibodies or fragments).
Owner:ARROWHEAD PHARMACEUTICALS INC
Anti-transferrin receptor antibodies with tailored affinity
Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.
Owner:F HOFFMANN LA ROCHE INC
Lyophilized preparation
[Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market.[Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.
Owner:JCR PHARMACEUTICALS CO LTD
Multispecific antibodies and uses thereof
PendingCN119173531ANervous disorderAntibody ingredientsNeurological problemsAntigen Binding Fragment
The invention provides a multispecific antibody or an antigen-binding fragment thereof. The multispecific antibody or the antigen-binding fragment thereof comprises at least one first antigen-binding region capable of specifically binding to pyroglutamate amyloid-beta and a second antigen-binding region capable of specifically binding to transferrin receptor (TfR). Methods of treating or detecting nervous system disorders and / or delivering therapeutic or diagnostic agents across the blood-brain barrier are also provided. Nucleic acids encoding the antibodies, vectors comprising the nucleic acids, recombinant host cells comprising the nucleic acids and / or vectors, and methods of producing the multispecific antibodies or antigen-binding fragments thereof are also described.
Owner:JANSSEN PHARMA NV
Bipeptide modified bionic nano-vesicle as well as preparation method and application thereof
PendingCN121846046ASsRNA viruses negative-senseOrganic active ingredientsDipeptideNeuronal protection
The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV
Polypeptide specifically binding to transferrin receptor and application thereof
The invention is applicable to the technical field of molecular biology, and provides a polypeptide specifically bound with a transferrin receptor, the polypeptide comprises a general formula of H1-H2-E1-E2-H3-H4-E3, and H1, H2, H3 and H4 independently comprise an alpha helical domain; the E1, the E2 and the E3 respectively and independently comprise a beta folding structural domain; when the polypeptide is combined with the hTfR1, transferrin is allowed to be combined to the hTfR1; the polypeptides are capable of binding and delivering oligonucleotides. The invention also provides a recombinant nucleic acid encoding the polypeptide, an expression vector comprising the recombinant nucleic acid, a recombinant host cell comprising the polypeptide, the nucleic acid and / or the expression vector, a conjugate of the polypeptide and oligonucleotide, and a corresponding pharmaceutical composition. The polypeptide disclosed by the invention can be highly specifically combined with hTfR1, so that accurate delivery of oligonucleotide is realized, and a practical basis is provided for treating diseases related to gene mutation.
Owner:CHAINGEN BIOPHARMA LTD
Multispecific antibodies and uses thereof
A multispecific antibody or antigen binding fragment thereof is provided, the multispecific antibody or antigen-binding fragment thereof comprises at least one first antigen-binding region capable of specifically binding to pyroglutamate amyloid-beta, a second antigen-binding region capable of specifically binding to transferrin receptor (TfR), and a third antigen-binding region capable of specifically binding to paired spiral filaments (PHF)-tau. Methods of treating or detecting nervous system disorders and / or delivering therapeutic or diagnostic agents across the blood-brain barrier are also provided. Nucleic acids encoding the antibodies, vectors comprising the nucleic acids, recombinant host cells comprising the nucleic acids and / or vectors, and methods of producing the multispecific antibodies or antigen-binding fragments thereof are also described.
Owner:JANSSEN PHARMA NV
